Topcon Healthcare

machineMD is a Swiss-based medical device company focused on innovating at the intersection of neuroscience and ophthalmology. It aims to significantly enhance the measurement of brain function, with the ultimate goal of enabling accurate, swift, and early diagnosis of brain disorders in primary and secondary care settings.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

RetiSpec is developing a non-invasive eye scanner for the early detection of Alzheimer’s Disease pathology years before symptoms occur. This enables clinicians to intervene with emerging therapeutics at an earlier stage when there's a chance of impacting the disease.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Toku Eyes creates diagnostic and screening tools to eliminate doctors' preventable health and vision deterioration. The company's tools provide a collection of artificial intelligence engines, each specialized in using a different imaging modality for diagnostics, prognostics, or health assessment purposes, allowing clinicians to aid in the prevention of diabetes and preventable blindness.

VISIA Imaging is a company focused on the design, development, and manufacturing of optical measurement and control equipment aimed at clinical diagnostics. It specializes in ophthalmology, cytogenetics, digital pathology, and immunoassays, with a particular emphasis on autoimmunity. The company produces automated liquid handling systems and digital imaging technologies that enhance immunodiagnostics and improve ophthalmic instruments. By researching and developing in-vitro diagnostic medical devices and software solutions, VISIA Imaging supports clinical laboratories and eye-care professionals in improving the efficiency and quality of their services.

Pangaea Data Limited is a technology company based in London, United Kingdom, that specializes in developing machine learning-based software for the biopharmaceutical and healthcare sectors. Founded in 2017, the company focuses on optimizing drug discovery and development by leveraging data from electronic health records and unstructured clinical notes. Its software solutions aim to identify patient cohorts based on specific clinical characteristics and symptoms, enhancing the relevance and utility of scientific and clinical data in these industries. Pangaea Data Limited was previously known as Pangaea Group Limited until it rebranded in May 2018.

RetInSight is a digital health company specializing in AI-driven retinal disease analysis. It develops a platform that uses AI to assess optical coherence tomography images, enabling precise diagnostics, tracking disease progression, and supporting treatment evaluation. This helps Austrian ophthalmologists and healthcare institutions enhance patient care, improve early disease detection, and optimize therapeutic decisions.